Silymarin: An interesting modality in dermatological therapeutics

Konchok Dorjay, Tasleem Arif, Mohammad Adil

Introduction
Silymarin is a plant-derived flavonoid which is extracted from the fruits and seeds of milk thistle (Silybum marianum L. Gaertn.), which belongs to the family Asteraceae. The extract of milk thistle has been used as a general medicinal herb used to treat the disorders of the spleen, liver, and gallbladder since as early as the 4th century BC, and was first reported by Theophrastus. In modern times, it has been primarily used in liver disorders including hepatitis, alcoholic liver diseases, and cirrhosis. Extensive chemoprevention studies have been performed in several in-vitro and in-vivo animal models to test the efficacy of silymarin and establish its mechanism of action against skin carcinogenesis. Silymarin is available in both topical and oral formulations and has been used in multiple conditions in dermatology, such as melanoma and nonmelanoma skin cancers, melasma, rosacea, psoriasis, atopic dermatitis, acne, wound healing, cosmeceuticals, as well as in anti-aging therapy. The photoprotective mechanisms of silymarin and silybin on the skin are mainly due to their ability to reduce and suppress the harmful effects of solar UV radiation, such as UV-induced oxidative stress, inflammation, immune responses, and DNA damage, as well as the induction of apoptosis. Pharmacological studies have revealed that silymarin is nontoxic even at higher than physiological doses, which suggests its safe use for the treatment of various diseases. No significant interaction of silymarin has been reported. The safety and efficacy of this herbal drug in liver disease has been analyzed in a review by Saller et al.

The main source of our information was PubMed, Google Scholar, and Scopus including original articles and review articles. The keywords “Silymarin,” “Silymarin in dermatology,” and “silibinin” were used for the search.

Structure
Silymarin is a complex mixture of four flavonolignan isomers, namely, silybin, isosilybin, silydianin, and silychristin with an empirical formula C30H22O16 [Figure 1]. Among the isomers, silybin is the major and most active component and represents approximately 60–70%, followed by silychristin (20%), silydianin (10%), and isosilybin (5%). Silymarin also contains taxifolin, which has significant free radical scavenging properties.

Pharmacokinetics
Silymarin is insoluble in water and is typically administered as a sugar-coated tablet or as an encapsulated standardized extract. The absorption by oral route is low. The peak plasma levels after an oral dose are achieved after 4–6 h in experimental animals and human beings and elimination half-life is approximately 6 h. About 20–40% of the administered dose of silymarin is excreted in bile as sulphates and glucuronide conjugates in human beings.

Mechanism of Action of Silymarin
Silymarin: Photocarcinogenesis and DNA repair
Table 1 shows the various mechanisms through which silymarin exerts its effects in various dermatological conditions. Ultraviolet radiation, especially ultraviolet B (UVB), is strongly absorbed by cellular DNA, resulting in DNA damage by the formation of cyclobutane pyrimidine dimers and 6–4 photoproducts. The oxidative stress involving generation of free radicals and reactive oxygen species (ROS) and depletion of antioxidant machinery are important factors with respect to the photocarcinogenesis of skin. Therefore, an agent having antioxidant properties such as silymarin that protects from UVB-induced DNA damage may be useful against photocarcinogenesis.

There is also significant reduction in the occurrence of post-UVB exposure sunburn and cutaneous edema by treatment with silymarin. Therefore, free radical scavenging system is a key pathway through which silymarin inhibits the process of carcinogenesis, which otherwise causes DNA damage. Other possible mechanisms observed in few animal studies have shown that silybin treatment...
activates p53, which is a key molecule in regulating DNA repair machinery along with cell cycle and apoptosis, and reduces the number of UVB-induced thymidine dimer positive cells in mouse skin epidermis.24,25

**Immunomodulatory effects of silymarin**

UVB-induced immunosuppression occurs due to the release of cytokines that permit the development of various skin tumors.17 It is now evident that many tumors, including melanoma and nonmelanoma skin cancers, appear to produce IL-10, and the immunosuppressive effects of IL-10 may be one of the mechanisms by which these tumors escape immune control.17-22 The reversal of UVB-induced immunosuppression by silymarin treatment was associated with decreased production of IL-10 in UV-irradiated skin and draining lymph nodes.14 The downregulation of contact hypersensitivity (CHS) responses caused by IL-10 may be mediated by the inhibition of antigen presentation. It was also shown that UV-induced infiltrating cells, particularly MHC+ CD11b+ cells (MHC type II), have a role in the UV-induced suppression of contact hypersensitivity.23 Therefore, reduction of MHC+ CD11b+ cell type in UVB-irradiated skin by silymarin prevents UV-induced suppression of contact hypersensitivity. This is also confirmed by the fact that silymarin treatment inhibited myeloperoxidase activity, in UVB-irradiated skin in an animal study.14

Gharagozloo et al. investigated the effect of silymarin on cell cycle and PI3K/Akt/mTOR signalling pathway of activated T lymphocytes in vitro.26 Peripheral blood mononuclear cells (PBMC) were isolated from healthy volunteers and cultured in complete RPMI (Roswell Park Memorial Institute) medium with 10, 50, and 100 µM silymarin or dimethyl sulphoxide (DMSO) and incubated for 24–96 h. A significant G1 arrest in the cell cycle of activated T lymphocytes was found after 96-h incubation with 100 µM silymarin without causing cell death. Silymarin also significantly inhibited the level of phospho-S6 ribosomal protein and mTOR activity in cell lysates of activated T cells after 72-h incubation in comparison with DMSO. The same author also observed that silymarin can inhibit T cell activation and proliferation, notably acting on the pathways of NF-kappa B activation/translocation and IL-2 production.18 These immunomodulatory effects of silymarin may have a significant impact in the fields of transplantation and autoimmunity.

**Silymarin and skin chemical carcinogenesis**

Silymarin has also shown promising results as a chemopreventive and/or therapeutic agent in various skin chemical carcinogenesis models in both animal and human studies.15,16,19 Overexpression of receptor and/or protein tyrosine kinases and the epidermal growth factor receptor (EGFR) signalling are important pathways in various cutaneous tumors, and oxidative stress has been identified as one of the inducers of these pathways.17,20 Studies have shown that silymarin inhibits both ligand-induced activation of receptor tyrosine kinase EGFR and its intrinsic kinase activity and subsequently inhibits the activation of an immediate downstream target.

**Silymarin and its antioxidant potential**

Silymarin: Opening new horizons in dermatological therapeutics

| Table 1: Mechanism of action of silymarin |
|------------------------------------------|
| **Silymarin and its antioxidant potential**24,25 |
| Inhibition of UVB-induced intracellular production of H$_2$O$_2$ |
| Inhibition of nitric oxide production by protection against UVB-induced expression of inducible nitric oxide synthase |
| Inhibits UVB-induced expression levels of ERK1/2 and p38 proteins of MAPK family |
| Inhibits chemical (TPA, BPO)-induced lipid peroxidation |
| Membrane stabilization |
| **Anti-inflammatory effect of silymarin**14,17-22 |
| Inhibits the expression of IL-1α as well as TNF-α |
| Inhibits myeloperoxidase activity |
| Inhibits lipooxygenase and cyclooxygenase activity resulting in the inhibition of prostaglandin metabolite formation |
| Inhibits the expression of inducible nitric oxide synthase as well as the production of nitric oxide in UV-treated skin |
| **Immunomodulatory effects of silymarin**14,25 |
| Decreases the production of IL-10 in UV-irradiated skin and draining lymph nodes |
| Inhibition of antigen presentation |
| Reduction in infiltration of MHC+ CD11b+ cell type into UVB-irradiated skin |
| Inhibition of myeloperoxidase activity |
| **Photoprotection and DNA repair effects of silymarin**24,25 |
| Anti-oxidant |
| Protects from UVB-induced DNA damage (photocarcinogenesis) |
| Activates p53 (key molecule in regulating DNA repair machinery along with cell cycle) and apoptosis |
| Reduces the number of UVB-induced thymine dimmers |
| **Effect of silymarin on EGFR-mediated mitogen signalling**26,27 |
| Inhibits activation of receptor tyrosine kinase EGFR and its intrinsic kinase activity and subsequently inhibits the activation of an immediate downstream target |
| **Inhibition of melanin synthesis**20,25 |
| Inhibits L-DOPA oxidation activity of tyrosinase |
| Decreases the expression of tyrosinase protein |
| UVB: Ultraviolet B, MAPK: Mitogen activated protein kinase, TPA: 12-O-tetradecanoylphorbol 13-acetate, BPO: Benzoyl peroxide, UV: Ultraviolet, DNA: Deoxyribonucleic acid, MHC: Major histocompatibility complex, DOPA: Dihydroxyphenylalanine, IL-1α: Interleukin 1 alpha, TNF-α: Tumor necrosis factor-alpha, EGRF: Epidermal growth factor receptor |

**Silymarin: Opening new horizons in dermatological therapeutics**

Skin is constantly exposed to free radical-generating agents such as solar UV radiation, ozone, and other environmental pollutants.32 Topical treatment with silymarin resulted in the inhibition of UVB-induced intracellular production of H$_2$O$_2$, inhibition of nitric
oxide production by protection against UVB-induced expression of inducible nitric oxide synthase, inhibition of infiltrating CD11b+ cell types, inhibition of UVB-induced expression levels of ERK1/2 and p38 proteins of mitogen activated protein kinase (MAPK) family, and subsequently inhibited the activation of NF-kB/p65 by inhibiting the degradation of IκBα and activation of IKKα. Together, these antioxidant activities demonstrate that silymarin has the ability to protect the skin from the adverse biological effects of UVB radiation via modulation of the MAPK and NF-kB signalling pathways and provide a molecular basis for the anti-carcinogenic effect.

Similarly, silymarin strongly inhibits TPA (12-O-tetradecanoylphorbol 13-acetate) and benzoyl peroxide (BPO)-induced lipid peroxidation in mouse skin epidermis supporting its strong in-vivo antioxidant activity.17

Anti-inflammatory effects of silymarin

The anti-inflammatory properties of silymarin have been studied by various authors.6,14,27

The mechanism of anti-inflammatory effect of silymarin observed in different studies are silymarin inhibits the expression of IL-1α as well as TNF-α, UVB, TPA, and benzoyl peroxide induced increase in myeloperoxidase activity, TPA and UVB induced lipooxygenase and cyclooxygenase activity resulting in inhibition of prostaglandin metabolite formation and expression of inducible nitric oxide synthase (iNOS).8,14,16,27

Inhibition of melanin synthesis

Silymarin inhibited L-dihydroxyphenylalanine (L-DOPA) oxidation activity of tyrosinase, the rate-limiting melanogenic enzyme, in cell based-systems, however it did not directly affect cell-free tyrosinase activity. Furthermore, western blot analysis indicated that silymarin decreased the expression of tyrosinase protein, thus explaining its effect in melasma.28,29 The various mechanisms of action of silymarin have been summarized in Table 1.

Application of Silymarin in Dermatology

The various possible clinical indications of silymarin have been listed in Table 2.

Skin cancers

Vaid et al. showed that silymarin not only prevents skin cancers but also prevents melanoma cell migration via the β-catenin signalling pathway.7 Chatterjee et al. observed the inhibition of development of nonmelanoma skin cancers in mice by applying silymarin-containing sunscreens via blocking the production of pyrimidine dimmers formed as a result of ultraviolet radiation exposure.28

Silymarin and ultraviolet protection

The UV protective effect of silymarin was reviewed by Mehraban and Feily.58 Silymarin decreased apoptosis and DNA damage caused by UV radiation via the nuclease excision repair mechanism on epidermal cells, which makes silymarin a viable option for prophylaxis of skin cancers.30 The inhibitory effects of silymarin on photocarcinogenesis by downregulation of the immunosuppressive cytokine and interleukin-10 and upregulation of the immunostimulator cytokine, interleukin-12, were also studied by Meeran et al.60

Silymarin and melasma

Altaii reported a study involving 96 adults clinically diagnosed as melasma.29 Patients were randomized in a double-blinded manner; Group I was prescribed silymarin (7 mg/ml) cream, Group II silymarin (14 mg/ml) cream, and Group III was administered placebo. Silymarin was applied topically to the affected areas twice daily for 4 weeks. The response was evaluated by lesion size, melasma area and severity index score, and physician global assessment. Clinically, all patients showed excellent pigment improvement and lesion size reduction with silymarin compared to that of the first week. In group I, complete clearing of the lesion was seen after the fourth week, in group II after 3 weeks of treatment, whereas no significant change was observed in group III. No side effects were observed.39 Silymarin was also beneficial in treating UVA-induced skin damage in a dose-dependent manner in in-vitro studies.40,41

Silymarin and rosacea

Berardesca et al. demonstrated that the combination therapy of silymarin and methylsulfonylmethane can be useful in the treatment of rosacea, especially in the rosacea subtype-1, erythematotelangiectatic phase.42 It was effective in reducing skin erythema, pruritus, papules and skin color.42

Silymarin as radioprotector and prevention of radiodermatitis

Adhikari et al. found silymarin to be a promising radioprotector.43 They used a fraction (INM-7035) with the composition of silybin A and B (39.9% and 57.4%, respectively). Free radical scavenging activities of INM-7035 against superoxide radicals (>68%), hydroxyl radicals (>33.75%), 2,2-diphenyl-1-picrylhydrazyl (DPPH) (67.2%), and 2,2-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) (32.4%) were also evaluated. INM-7035 completely inhibited lipid peroxidative stress in case of membranes against supra-lethal radiation stress in the liposomal system. The ability of INM-7035 to modulate

| Application of silymarin in dermatology* |
|----------------------------------------|
| Skin cancers\( ^{5,30} \) |
| Sunscreens\( ^{14,38} \) |
| Melasma (Ib)\( ^{39,40,41} \) |
| Rosacea (III)\( ^{42} \) |
| Radioprotector\( ^{43} \) |
| Psoriasis\( ^{40,45} \) |
| Acne (Ib)\( ^{46} \) |
| Actinic keratosis prevention\( ^{47} \) |
| Cosmeceuticals\( ^{48} \) |
| Atopic dermatitis\( ^{49,50} \) |
| Wound healing\( ^{45,51} \) |
| Anti-aging\( ^{52} \) |
| Irritant contact dermatitis\( ^{53} \) |
| Prevention of radiodermatitis (III)\( ^{54} \) |
| Antibacterial\( ^{55} \) |
| Autoimmune disorders\( ^{16} \) |

*Categories of evidence - Ia: Evidence for meta-analysis of randomized controlled trials, Ib: Evidence from at least one randomized controlled trial, Iia: Evidence from at least one controlled study without randomization, Iib: Evidence from at least one other type of quasi-experimental study, II: Evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies and case-control studies, IV: Evidence from expert committee reports or opinions or clinical experience of respected authorities, or both
the levels of NF-kappa B, indicated its inherent potential as a radioprotective bioactive constituent.43

A study was conducted in 101 breast cancer patients undergoing postsurgical radiotherapy by Becker-Schiebe et al.46 Of these, 51 patients were treated with silymarin-based cream. Only 9.8% of patients using silymarin-based cream showed grade 2 toxicity in week 5 of radiotherapy in comparison to 52% with the nonsilymarin-based group. At the end of radiotherapy, 23.5% of patients in the silymarin-based study group developed no skin reactions versus 2% in nonsilymarin-based group. They concluded that silymarin cream may be promising in the prevention of acute skin lesions caused by radiotherapy of breast cancer patients.46

Silymarin and psoriasis

There are anecdotal reports of efficacy of silymarin in the treatment of psoriasis.44,45 Khan et al. found that silymarin gel has promising antipsoriatic activity.61

Silymarin and acne

A randomized, prospective clinical trial on 56 patients in the age range of 14–35 years showed the beneficial effects of silymarin, N-acetylcysteine, and selenium in patients with acne vulgaris, as indicated by the clinical improvement and biochemical findings.46

Actinic keratosis prevention

There are various agents that can be used in the prevention of AK, with silymarin being one of them. Berman and Amini have reviewed the pharmacotherapy of actinic keratosis (AK).47

Atopic dermatitis

The effect of topical silymarin in atopic dermatitis induced by dust mite extract in NC/Nga mice was studied by Kang et al. who found that it reduced atopic dermatitis-like lesions and suppressed mast cell infiltration in mice skin.48 In addition, silymarin also reduced plasma levels of IL-4 and IgE in these mice. Hence, silymarin might be beneficial for the treatment of AD.49 Recently, Mady et al. showed that silymarin pluronic-lecithin organogel (PLO) formulation significantly relieved inflammatory symptoms of AD such as redness, swelling, and inflammation.50

Silymarin and contact dermatitis

Topical silymarin has shown benefit when applied to skin damaged by chemical induced irritant contact dermatitis.55

Wound healing

Sharifi et al. carried out a study to evaluate the effect of topical application of silymarin on excision wounds in rats.51 Rats were divided into three groups viz. control, vehicle, and treatment. Vehicle and treatment groups received polyethylene glycol and silymarin, respectively. They found that silymarin significantly stimulates epithelialization and reduces inflammation in full-thickness wounds in rats. Oryan et al. also found that topical application of silymarin improved the morphological, biochemical, and biomechanical properties of experimentally-induced wound defects in rats.52 In another study, Tabandeh et al. found that silibinin acts by increasing stromelysin-1 gene expression and extracellular matrix constituents including glycosaminoglycans and collagen contents and promotes a faster wound healing process.53 Therefore, silymarin has the potential of being one of the therapeutic options for wound healing.

Silymarin: Opening new horizons in dermatological therapeutics

Silymarin as anti-ageing agent, sunscreen, and cosmeceutical

Pientaweeratch et al. studied the anti-aging property of amla, silymarin, and sapota and found these agents to have antioxidant, anti-collagenase, and anti-elastase activities in in-vitro studies.54 They found that the extracts might be added as a mixture to gain overall anti-aging effects. Topical and oral anti-oxidants such as silymarin, slow ageing processes and act as sunscreens.55 Oxidative stress is one of the major mechanisms for skin aging, and silibinin with its proven antioxidant activity could be useful for treating many dermatologic conditions as well as skin aging. Thus, this supports the scientific rationale for the effective use of silibinin in cosmeceutical preparations.56

Antibacterial and antiadherence activities of silymarin

Evren et al. studied the antibacterial and antiadherent properties of silymarin and its effects on bacterial biofilm viability. A minimum inhibitory concentration between 60 and 120 µg/mL inhibited gram positive bacteria. The biofilm viabilities decreased to 13% and 46% at 1 and 0.5 mmol/L concentrations, respectively. There was also a marked reduction in biofilm/adherence formation in the silymarin-treated group in comparison to silymarin-untreated group. This study showed that silymarin is endowed with antibacterial and anti-adherence/biofilm properties.57

Drug interaction

The major concern for the use of silymarin is liver toxicity which it may cause via the inhibition or induction of cytochrome-P450 and drug–drug interaction. However, no significant interaction has been reported till now.58 Silymarin has been found to be hepatoprotective in children receiving methotrexate-based chemotherapy protocols.59

Adverse effects

Silymarin is reported to have a very good safety profile. Both animal and human studies have shown that silymarin is nontoxic even when given in higher doses (>1500 mg/day). However, a laxative effect is noted at these doses. Most common adverse effect observed is that of the gastrointestinal tract [Table 3] such as bloating, dyspepsia, nausea, irregular stools, and diarrhoea. These were observed in 2–10% of patients in clinical trials, which were similar to placebo.60 Others adverse effects include pruritus, headache, exanthema, malaise, asthenia, and vertigo.6 Some serious adverse events were reported in three patients by Jacobs et al. A 57-year-old lady developed serious symptoms of gastroenteritis associated with collapse whereas the other two reported cases were allergic in nature after ingestion of herbal tea containing silymarin.64 Silymarin increases lactation most probably by elevating the circulating prolactin level and was traditionally used by nursing mothers for stimulating milk production. However, no studies are available regarding its safety in pregnant women and newborns while on breast milk.65,66

Conclusion

Silymarin is widely used as a hepatoprotective agent for various disorders of the liver because of its good safety profile and effectiveness. Recently, it’s use has been investigated in many dermatological conditions due to its anti-oxidant, anti-inflammatory, immunomodulatory, and membrane-stabilizing properties. Although silymarin has shown promising results in various dermatologic conditions in humans, most of the publications available are on animal studies. At present, silymarin is being used for various skin disorders such as melasma, anti-aging, sunscreen, acne, rosacea,
Dorjay, et al. Silymarin: Opening new horizons in dermatological therapeutics

**Table 3: Adverse effects of silymarin**

| Common adverse effects                  |
|----------------------------------------|
| Bloating                               |
| Dyspepsia                              |
| Nausea                                 |
| Irregular stools and diarrhoea         |

| Serious adverse effects                |
|----------------------------------------|
| Collapse                               |
| Allergic reaction                      |

| Less common adverse effects            |
|----------------------------------------|
| Pruritus                               |
| Headache                               |
| Exantheme                              |
| Malaise                                |
| Asthenia                               |
| Vertigo                                |

Psoriasis, skin cancer, photoprotection, cosmeceuticals, and so on. However, the evidence base in humans is still not very strong, and more clinical trials are needed to evaluate the clinical efficacy of standardized silymarin preparations against various dermatologic conditions.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Wagner H, Diesel P, Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittelforschung 1974;24:466‑71.
2. Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology 1999;30:1099‑104.
3. Ferenci P, DragošVES B, Dittrich H, Frank H, Benda L, Locs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1998;9:105‑13.
4. SalMI HAT, Sama S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 1982;17:517‑21.
5. SalMI HAT, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035‑63.
6. KatIyar SK, Koman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997;89:556‑66.
7. Lahiri-Chatterjee M, KatIyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59:622‑32.
8. Vaid M, Prasad R, San Q, KatIyar SK. Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS One 2011;6:e23000.
9. Kren V, Walterová D. Silybin and silymarin – New effects and applications. Biomed Pap Med Fac Univer Palacky Olomouc Czech Repub 2005;149:29‑41.
10. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491‑504.
11. Morazzoni P, Montalbetti A, Malderrino S, Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab

Silymarin: Opening new horizons in dermatological therapeutics

12. Luper S. A review of plants used in the treatment of liver disease: Part I. Altern Med Rev 1998;3:410‑21.
13. Lorenz D, Lücker PW, Mennicke WH, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 1984;6:655‑61.
14. KatIyar SK. Treatment of silymarin, a plant flavonoid, prevents ultraviolet light‑induced immune suppression and oxidative stress in mouse skin. Int J Oncol 2002;21:1213‑22.
15. ZI X, Mukhtar H, Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin. Inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun 1997;239:334‑9.
16. Zhao J, Lahiri-Chatterjee M, Sharma Y, Agarwal R. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide‑induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis 2000;21:811‑812.
17. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995;267:1782‑8.
18. Gharaogozoo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, et al. Silymarin suppress CD4+ T cell activation and proliferation: Effects on NF‑kappa B activity and IL‑2 production. Pharmacol Res 2010;61:405‑9.
19. ZI X, Agarwal R. Modulation of mitogen‑activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 1999;263:528‑36.
20. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 2002;4:655‑63.
21. Ahmad N, Gali H, Javed S, Agarwal R. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem Biophys Res Commun 1998;247:294‑301.
22. KatIyar SK, Meleth S, Sharma SD. Silymarin, a flavonoid from milk thistle (Silybum marianum L.), inhibits UV‑induced oxidative stress through targeting infiltrating CD11b+ cells in mouse skin. Photochem Photobiol 2008;84:266‑71.
23. Hammerberg C, Duraiswamy N, Cooper KD. Reversal of immunosuppression inducible through ultraviolet‑exposed skin by in vivo anti‑CD11b treatment. J Immunol 1996;157:5254‑61.
24. Dhanalkashmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin prevents ultraviolet radiation‑caused skin damages in SKH‑1 hairless mice via a decrease in thymine dimer positive cells and an up‑regulation of p53‑p21/Cip1 in epidermis. Carcinogenesis 2004;25:1459‑65.
25. Mallikarjuna GU, Dhanalkashmi S, Singh RP, Agarwal R. Dietary feeding of silibinin prevents early biomarkers of UVB radiation‑induced carcinogenesis in SKH‑1 hairless mouse epidermis. Cancer Epidemiol Biomarkers Prev 2005;14:1344‑9.
26. Gharaogozoo M, Javid EN, Rezaei A, Mousavizadeh K. Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: Therapeutic implications for autoimmune diseases. Basic Clin Pharmacol Toxicol 2013;112:251‑6.
27. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF‑induced activation of NF‑kappa B, c‑Jun N‑terminal kinase, and apoptosis. J Immunol 1999;163:6800‑9.
28. Choo SJ, Ryoo II, Kim YH, Xu GH, Kim WG, Kim KH, et al. Silymarin inhibits melanin synthesis in melanocyte cells. J Pharm Pharmacol 2009;61:663‑7.
29. Alatai T. The treatment of melasma by silymarin cream. BMC Dermatol 2012;18:12.
30. Mitchell DL, Nairn RS. The biology of the (6‑4) photoproduct. Photochem Photobiol 1989;49:805‑19.
31. Tyrrell RM. Oxidant, antioxidant status and photocarcinogenesis: The role of gene activation. Photochem Photobiol 1996;63:380‑3.
32. Mukhtar H, Elmets CA. Photocarcinogenesis: Mechanisms, models and human health implications. Photochem Photobiol 1996;63:356‑7.
33. Moodycliffe AM, Ullrich SE. The role of cis‑UCA in ultraviolet B radiation induced immunosuppression delayed‑type hypersensitivity (DTH) and contact hypersensitivity (CHS) responses. Photochem Photobiol 1995;61:535‑41.
34. Dummer W, Becker JC, SchwaaF M, Leverkus M, Moll T, Bröcker EB.
Dorjay, et al.

Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995;5:67-8.

35. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, et al. IL-10 production in cutaneous basal and squamous cell carcinomas: A mechanism for evading the local T cell immune response. J Immunol 1995;155:2240-7.

36. Gu M, Dhanalakshmi S, Mohan S, Singh RP, Agarwal R. Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis 2005;26:1404-13.

37. Zhao J, Sharma Y, Agarwal R. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1alpha expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor promotion. Mol Carcinog 1999;26:321-33.

38. Chatterjee ML, Agarwal R, Mukhtar H. Ultraviolet B radiation-induced DNA lesions in mouse epidermis: An assessment using a novel 32P-postlabelling technique. Biochem Biophys Res Commun 1996;229:590-5.

39. Hassan I, Dorjay K, Sami A, Anwar H. Sunscreens and antioxidants as photo-protective measures: An update. Our Dermatol Online 2013;4:369-74.

40. Svobodová A, Zdarilová A, Malisková J, Mikulková H, Walterová D, Vostálová J. Attenuation of UVA-induced oxidative damage to human keratinocytes by silymarin. J Dermatol Sci 2007;46:21-30.

41. Svobodová A, Zdarilová A, Walterová D, Vostálová J. Flavonolignans from Silybum marianum moderate UVA-induced oxidative damage to Hacat keratinocytes. J Dermatol Sci 2007;48:213-24.

42. Berardesca E, Cameli N, Cavallotti C, Levy JL, Piérard GE, de Paoli Ambrosi G. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: Clinical and instrumental evaluation. J Cosmet Dermatol 2008;7:8-14.

43. Adhikari M, Arora R, Chawla R, Sharma J, Dhaker AS, Gupta D, et al. Evaluation of silymarin as a promising radioprotector. Z Naturforsch C 2010;65:337-46.

44. Fiebrich F, Koch H. Silymarin, an inhibitor of lipoxygenase. Experientia 1979;35:1548-60.

45. Koch HP, Bachner J, Löfler E. Silymarin: Potent inhibitor of cyclic AMP phosphodiesterase. Methods Find Exp Clin Pharmacol 1985;7:409-13.

46. Al-Anbari HH, Sahib AS, Abu Raghib AR. Effects of silymarin, N-acetylcysteine and selenium in the treatment of papulopustular acne. Expert Opin Pharmacother 2012;13:1847-71.

47. Berman B, Amini S. Pharmacotherapy of actinic keratosis: An update. Expert Opin Pharmacother 2012;13:1847-71.

48. Singh RP, Agarwal R. Cosmeceuticals and silibinin. Clin Dermatol 2009;27:479-84.

49. Kang JS, Yoon WK, Han MH, Lee H, Lee CW, Lee KH, et al. Inhibition of atopic dermatitis by topical application of silymarin in NC/Nga mice. Int Immunopharmacol 2008;8:1475-80.

50. Mady FM, Essa H, El-Amamawi T, Abdelkader H, Hussein AK. Formulation and clinical evaluation of silymarin pluri-necithin organogels for treatment of atopic dermatitis. Drug Des Devel Ther 2016;10:1101-10.